Syphilis Immunoassay Diagnostics Market By Product Type (Analyzers, Kits and reagents), By Technology (CLIA, ELISA), By End User (Blood Banks, Diagnostic Labs, Hospitals): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global syphilis immunoassay diagnostics market was valued at $315.5 million in 2021, and is projected to reach $446.0 million by 2031, registering a CAGR of 3.5% from 2022 to 2031.
Syphilis is a chronic bacterial infection that can be transmitted through sexual contact. It is caused by a type of bacteria known as Treponema pallidum. The four stages of syphilis include primary, secondary, latent, and tertiary. The primary stage of syphilis occurs about 3 to 4 weeks after a person contracts the bacteria. Skin rashes and a sore throat may develop during the second stage of syphilis. The primary and secondary symptoms disappear, and there won’t be any noticeable symptoms at the latent stage of syphilis. The tertiary stage can cause blindness, loss of hearing, and mental health conditions. The diagnosis of this disease includes the collection of spinal fluid for the screening test of syphilis. Moreover, the blood test for syphilis tests for antibodies directed at the syphilis organism (Treponema pallidum). The available tests for syphilis include the microhemagglutination assay for T pallidum, the T pallidum particle agglutination, the T pallidum hemagglutination assay, the fluorescent treponemal antibody absorbed (FTA-ABS) test, and chemoluminescence immunoassays and enzyme immunoassays that detect Treponemal antibodies.
The growth of the syphilis immunoassay diagnostics market is driven by rising in socioeconomic factors such as sexually transmitted diseases and an increase in the proportion of sex under the influence of numerous drugs such as heroin, cocaine, methamphetamine, cannabis, benzodiazepines, and alcohol. Moreover, the increase in rates of fatal syphilis infections, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing also help in the growth of the market. For instance, according to the data from World Health Organization (WHO), there were an estimated 374 million new infections with 1 of 4 STIs like chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million) in 2020. However, a lack of knowledge among individuals in emerging economies is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.
The global syphilis immunoassay diagnostics market is segmented based on product type, technology, end-user, and region. As per product type, the market is divided into analyzers and kits & reagents. Depending on the technology, the market is bifurcated into CLIA and ELISA. According to end users, the market is classified into blood banks, diagnostic labs, and hospitals. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the syphilis immunoassay diagnostics market analysis from 2021 to 2031 to identify the prevailing syphilis immunoassay diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the syphilis immunoassay diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global syphilis immunoassay diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product Type
Analyzers
Kits and reagents
By Technology
CLIA
ELISA
By End User
Blood Banks
Diagnostic Labs
Hospitals
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
BioRad Laboratories Inc
Danaher Corporation
BECTON DICKINSON & COMPANY
, F. Hoffmann-La Roche AG
Siemens Healthineers AG
Diasorin S.P.A
Abbott Laboratories
Fujirebio
, BioMerieux SA
Shenzhen New Industries Biomedical Engineering Co. Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook